Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SkyWest Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while SkyWest Inc trades at $99.72 (market cap $3.96B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.1× SkyWest Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SKYW | |
|---|---|---|
Market Cap | $39.89B | $3.96B |
Sector | Health | Technology |
52-Week High | $491.22 | $123.72 |
52-Week Low | $278.09 | $78.40 |
Enterprise Value | $38.15B | $5.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SkyWest (SKYW) trades at $99.72, down 0.29% on the day, with strong technical momentum showing bullish moving averages and key support at $98. The company maintains solid fundamentals with a P/E of 9.57, net income margin of 10.42%, and consistent earnings beats in recent quarters. Recent leadership changes include Wade Steel's promotion to President and COO of SkyWest Airlines.
SkyWest presents attractive valuation with upside to the $109.33 consensus price target, supported by strong analyst sentiment (56% buy ratings). Key risks include rising fuel costs highlighted in recent government data showing 84% year-over-year increases, which could pressure airline profitability despite current operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
